GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascelia Pharma AB (OSTO:ACE) » Definitions » PS Ratio

Ascelia Pharma AB (OSTO:ACE) PS Ratio : (As of May. 14, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Ascelia Pharma AB PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Ascelia Pharma AB's share price is kr10.00. Ascelia Pharma AB's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was kr0.00. Hence, Ascelia Pharma AB's PS Ratio for today is .

The historical rank and industry rank for Ascelia Pharma AB's PS Ratio or its related term are showing as below:

OSTO:ACE's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 8.98
* Ranked among companies with meaningful PS Ratio only.

Ascelia Pharma AB's Revenue per Sharefor the three months ended in Dec. 2023 was kr0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was kr0.00.

Back to Basics: PS Ratio


Ascelia Pharma AB PS Ratio Historical Data

The historical data trend for Ascelia Pharma AB's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascelia Pharma AB PS Ratio Chart

Ascelia Pharma AB Annual Data
Trend Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial - - - - -

Ascelia Pharma AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ascelia Pharma AB's PS Ratio

For the Biotechnology subindustry, Ascelia Pharma AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascelia Pharma AB's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascelia Pharma AB's PS Ratio distribution charts can be found below:

* The bar in red indicates where Ascelia Pharma AB's PS Ratio falls into.



Ascelia Pharma AB PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Ascelia Pharma AB's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=10.00/0
=

Ascelia Pharma AB's Share Price of today is kr10.00.
Ascelia Pharma AB's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Ascelia Pharma AB  (OSTO:ACE) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Ascelia Pharma AB PS Ratio Related Terms

Thank you for viewing the detailed overview of Ascelia Pharma AB's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascelia Pharma AB (OSTO:ACE) Business Description

Traded in Other Exchanges
Address
Hyllie Boulevard 34, Malmo, SWE, SE-215 32
Ascelia Pharma AB is an oncology-dedicated drug development company located in Malmo, Sweden, focused on the development of novel drugs to improve the life expectancy and quality of life for people living with cancer. The company is focused on two clinical-stage product candidates under development: Mangoral and Oncoral.

Ascelia Pharma AB (OSTO:ACE) Headlines

No Headlines